MCID: PSR002
MIFTS: 65

Psoriasis

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Psoriasis

MalaCards integrated aliases for Psoriasis:

Name: Psoriasis 12 76 53 37 29 55 43 3 15 63 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8893
ICD10 33 L40 L40.9
MeSH 44 D011565
NCIt 50 C3346
KEGG 37 H01656
UMLS 73 C0033860

Summaries for Psoriasis

MedlinePlus : 43 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast. Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include Infections Stress Dry skin Certain medicines Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Psoriasis is related to guttate psoriasis and pustular psoriasis, and has symptoms including exanthema, pruritus and psoriasiform rash. An important gene associated with Psoriasis is MIR203A (MicroRNA 203a
The up-regulation of miR-203 in psoriatic plaques was concurrent with the down-regulation of an evolutionary conserved target of miR-203, suppressor of cytokine signaling 3 (SOCS-3), which is involved in inflammatory responses and keratinocyte functions.), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Rayos and Zinc have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

NIH Rare Diseases : 53 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. The skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. A problem with the immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in the skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because the cells rise too fast. Although symptoms may come and go, for many, psoriasis is a lifelong condition. Infections, stress, dry skin and certain medications may make symptoms worse. Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medications and light therapy.

CDC : 3 Psoriasis is a chronic autoimmune skin disease that speeds up the growth cycle of skin cells.

PubMed Health : 63 About psoriasis: Psoriasis is a non-contagious inflammatory disease. The main symptoms are reddish, scaly patches of skin that may itch.It is a chronic condition that is typically associated with periods of more severe skin problems (flare-ups) followed by periods of milder skin problems or none at all. Various treatments can relieve the symptoms, but there is no cure for psoriasis.Its severity can vary quite a lot. In some people it is bothersome more than anything else, and they can cope with it quite well. Others feel that it has a major effect on their quality of life, since the treatment and skin care can take a long time. Many people are also unhappy about having visible reddened and scaly skin patches – especially if they are on exposed areas of their body.Sometimes the inflammation that is causing the psoriasis affects other parts of the body too, such as the joints or nails.

Wikipedia : 76 Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. These skin... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 guttate psoriasis 35.5 CDSN HLA-C
2 pustular psoriasis 35.4 CARD14 IL36RN
3 psoriatic arthritis 34.8 HLA-C IL36RN MIR146A
4 impetigo herpetiformis 33.9 CARD14 IL36RN
5 geographic tongue 33.4 HLA-C IL36RN
6 skin disease 31.9 CARD14 CDSN HLA-C IL36RN MIR203A
7 pityriasis rubra pilaris 31.7 CARD14 IL36RN
8 nonalcoholic fatty liver disease 29.9 MIR203A MIR31
9 psoriasis 14, pustular 12.6
10 psoriasis 1 12.5
11 psoriasis 13 12.4
12 psoriasis 7 12.3
13 psoriasis 11 12.3
14 psoriasis 2 12.3
15 psoriasis 15, pustular 12.2
16 pustulosis palmaris et plantaris 12.0
17 psoriasis 6 12.0
18 psoriasis 3 11.9
19 psoriasis 4 11.9
20 psoriasis 5 11.9
21 psoriasis 8 11.9
22 psoriasis 10 11.9
23 psoriasis 12 11.9
24 mental retardation and psoriasis 11.9
25 psoriasis 9 11.9
26 psoriatic juvenile idiopathic arthritis 11.8
27 pustulosis of palm and sole 11.6
28 tranebjaerg svejgaard syndrome 11.6
29 arthritis 11.3
30 parapsoriasis 11.3
31 subacute cutaneous lupus erythematosus 11.1
32 chronic recurrent multifocal osteomyelitis 11.1
33 singleton-merten syndrome 1 10.9
34 systemic onset juvenile idiopathic arthritis 10.9
35 ovarian serous carcinoma 10.9 MIR200A MIR21
36 nail disorder, nonsyndromic congenital, 1 10.8
37 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
38 singleton-merten syndrome 2 10.8
39 temporomandibular ankylosis 10.8
40 primary cutaneous amyloidosis 10.8
41 singleton-merten syndrome 10.8
42 leiomyoma, uterine 10.7 MIR203A MIR21
43 thyroid cancer, nonmedullary, 1 10.7 MIR146A MIR200A MIR21
44 oral squamous cell carcinoma 10.6 MIR146A MIR203A MIR21 MIR31
45 dermatitis 10.5
46 dermatitis, atopic 10.4
47 endotheliitis 10.2
48 rheumatoid arthritis 10.2
49 bullous pemphigoid 10.1
50 alopecia 10.1

Graphical network of the top 20 diseases related to Psoriasis:



Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:


exanthema, pruritus, psoriasiform rash

Drugs & Therapeutics for Psoriasis

PubMedHealth treatment related to Psoriasis: 63

There are various treatment options for psoriasis:Basic therapy (skin care): Care of the affected areas of skin using lipid-replenishing ointments, creams or lotions. This is done to keep the skin supple, protect it from injury and relieve itching. Some products also contain medications that are supposed to reduce shedding, such as urea or salicylic acid.Topical treatment: Products containing corticosteroids or vitamin D analogues are typically used in topical treatment (treatment applied to the skin from the outside). These are available in the form of creams, ointments lotions or foams.Light therapy: Light therapy, also known as phototherapy, involves exposing the plaques to ultraviolet light (UV light). The UV light reduces inflammation in the skin, and also slows the production of cells. Sometimes medications called psoralens are used in combination with light therapy. Psoralens make the skin more sensitive to light. Light therapy is best suited for people who have moderate or severe psoriasis and in whom topical treatment alone wasn't effective enough.Medications that are taken orally or injected: These medicines are a treatment option for moderate or severe psoriasis. They inhibit the body's immune response. Methotrexate (MTX), fumaric acid esters, apremilast and biological drugs (biologics) are commonly used for this purpose.Basic moisturizing skin care is always recommended for psoriasis – during periods without any skin problems, too.There are also many herbal medicines for the treatment of psoriasis, including extracts of barberry (Mahonia aquifolium), birch bark or aloe vera. The effectiveness of these herbal medicines hasn't been tested in any good-quality studies, though. So it isn't known whether they can help.Some studies suggest that people with psoriasis who are overweight can improve the condition of their skin by losing a few pounds.It is sometimes claimed that a tonsillectomy (removal of the tonsils) can relieve psoriasis symptoms, but there hasn't been much research in this area. Tonsillectomy usually isn't recommended because the operation may cause complications such as infections, bleeding and changes to the person's voice. There are also no studies showing that having your tonsils out can cure or prevent psoriasis.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Rayos 18 PREDNISONE Horizon Pharma July of 2012

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 430)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 23994
2
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
5
Acitretin Approved Phase 4,Phase 3,Phase 2,Not Applicable 55079-83-9 6437841 5284513
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
7
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 185243-69-0
8
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
9
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
10
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 378-44-9 9782
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
12
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
13
Desonide Approved, Investigational Phase 4 638-94-8 5311066
14
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 815610-63-0
15
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118292-40-3 5381
16
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
18
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
19
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 124-94-7 31307
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
23
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
24
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
25
Desoximetasone Approved Phase 4,Phase 3,Phase 2 382-67-2 5311067
26
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
27
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
28
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
29
Anthralin Approved Phase 4 1143-38-0
30
Dapsone Approved, Investigational Phase 4 80-08-0 2955
31
Insulin glulisine Approved Phase 4 207748-29-6
32
Capsaicin Approved Phase 4 404-86-4 1548943
33
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 32222-06-3 134070 5280453
34
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
36 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
38
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 98-92-0 936
39
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 59-67-6 938
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
41
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
42
Butyric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107-92-6 264
43 Amotosalen Phase 4,Phase 2,Not Applicable,Early Phase 1
44 beta-endorphin Phase 4
45 Betamethasone Valerate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2152-44-5
46 Calcipotriene Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Ficusin Phase 4,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1469)
# Name Status NCT ID Phase Drugs
1 The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
2 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate Unknown status NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
3 Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis Unknown status NCT02144857 Phase 4 etanercept;ustekinumab;cyclosporine
4 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
5 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
6 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
7 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
9 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
10 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
11 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
12 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
13 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
14 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
15 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
16 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
17 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
18 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray Completed NCT02985736 Phase 4 Topicort Topical Spray
19 Topical Psoriasis Study for Patients Receiving Biologic Therapy Completed NCT02983981 Phase 4 Topicort Topical Spray
20 Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis Completed NCT00924950 Phase 4 Taclonex Ointment and Hydrogel Patch;Taclonex Ointment
21 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
22 Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
23 Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis Completed NCT00990561 Phase 4 Ultravate ointment twice daily + LacHydrin lotion twice daily;Ultravate ointment once daily + LacHydrin lotion twice daily
24 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Completed NCT00992394 Phase 4 etanercept;etanercept
25 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
26 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
27 A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
28 Moderate to Severe Plaque Psoriasis With Scalp Involvement Completed NCT00791765 Phase 4
29 Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment
30 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment Completed NCT01511315 Phase 4 Ustekinumab
31 Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis Completed NCT01039142 Phase 4 Acitretin
32 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp Completed NCT00881868 Phase 4 clobetasol propionate spray 0.05%;Vehicle spray
33 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis Completed NCT01265823 Phase 4
34 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp Completed NCT00669214 Phase 4 efalizumab;placebo
35 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
36 Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects Completed NCT00658606 Phase 4 alefacept
37 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis Completed NCT00332332 Phase 4
38 Comparison Study of Psoriasis Severity Assessment Tools Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
39 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed NCT00249808 Phase 4 Efalizumab - anti-CD11a recombinant human monoclonal antibody
40 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis Completed NCT00655564 Phase 4 Alefacept
41 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4 Etanercept;Etanercept + Acitretin;Acitretin
42 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
43 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
44 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) Completed NCT00686595 Phase 4
45 Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis Completed NCT01111123 Phase 4 Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%);Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
46 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed NCT02752776 Phase 4 Secukinumab
47 Apremilast in Palmo-Plantar Psoriasis Completed NCT02400749 Phase 4 Apremilast;Placebo
48 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4 Adalimumab
49 Mechanism of Action Study for Psoriasis Completed NCT00932113 Phase 4 Methotrexate;Adalimumab (Humira)
50 Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

# Genetic test Affiliating Genes
1 Psoriasis 29

Anatomical Context for Psoriasis

MalaCards organs/tissues related to Psoriasis:

41
Skin, Testes, T Cells, Endothelial, Liver, Neutrophil, Monocytes

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 3512)
# Title Authors Year
1
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with SevereA Itch. ( 29317264 )
2018
2
Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. ( 29705819 )
2018
3
Inflammatory bowel disease and acute anterior uveitis, but not psoriasis are associated with disease duration in Axial SpA: results from the (Be)Giant and ASPECT cohort. ( 29740978 )
2018
4
The heterogeneous mutational landscape of pustular psoriasis. ( 29595236 )
2018
5
RNA sequencing-based longitudinal transcriptomic profiling gives novel insights into the disease mechanism of generalized pustular psoriasis. ( 29871627 )
2018
6
Pustular psoriasis and related pustular skin diseases. ( 29333670 )
2018
7
Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris - Lessons from a family with PRP and psoriasis. ( 29704870 )
2018
8
Retinoic acid syndrome in a elderly male with psoriasis- A case report. ( 29977766 )
2018
9
Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study). ( 29444376 )
2018
10
Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy. ( 29689136 )
2018
11
Mycosis fungoides in patients with psoriasis: an ongoing issue. ( 29336316 )
2018
12
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
13
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. ( 29380251 )
2018
14
Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. ( 29395573 )
2018
15
Assessing the Importance of Treatment Goals in Patients with Psoriasis: Analytic Hierarchy Process vs. Likert Scales. ( 29450833 )
2018
16
T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. ( 29971067 )
2018
17
Pustular psoriasis of pregnancy: current perspectives. ( 29520163 )
2018
18
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
19
CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. ( 29477734 )
2018
20
Branch Duct-type Intraductal Papillary Mucinous Neoplasm Presenting as Paraneoplastic Small Plaque Para-psoriasis. ( 29441297 )
2018
21
Psoriasis in Israel: demographic, epidemiology, and healthcare services utilization. ( 29978903 )
2018
22
Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. ( 29862046 )
2018
23
Anti-Programmed Cell Death-1-Induced Plaque and Guttate Psoriasis. ( 29527039 )
2018
24
An infant with generalized pustular psoriasis and geographic tongue had a heterozygous IL36RN mutation and IgG2 deficiency. ( 29454537 )
2018
25
A case of pustular psoriasis of pregnancy with positive maternal-fetal outcomes. ( 29763478 )
2018
26
Pediatric case of generalized pustular psoriasis developing acute pancreatitis. ( 29655246 )
2018
27
[EXPRESS] Quantitative Evaluation to Efficacy and Safety of Therapies for Psoriasis: A Network Meta-Analysis. ( 29448914 )
2018
28
Acrodermatitis continua of Hallopeau and geographic tongue are variants of pustular psoriasis. ( 29687071 )
2018
29
Relationship between etanercept and thyroid function in patients with psoriasis vulgaris. ( 29440950 )
2018
30
ARDS complicating pustular psoriasis: treatment with low-dose corticosteroids, vitamin C and thiamine. ( 29420246 )
2018
31
Genetic background and therapeutic response in generalized pustular psoriasis patients treated with granulocyte and monocyte adsorption apheresis. ( 29380726 )
2018
32
Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis. ( 29554401 )
2018
33
Evaluation of Erythroid Disturbance and Thiol-Disulphide Homeostasis in Patients with Psoriasis. ( 29967791 )
2018
34
Auftreten einer Psoriasis vulgaris bei einem Patienten mit Pemphigus vulgaris unter Kortikosteroidtherapie. ( 29750447 )
2018
35
Increased psoriasis frequency in patients with familial Mediterranean fever. ( 29363386 )
2018
36
Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. ( 29795283 )
2018
37
Autoimmune disease: Targeting glucose transport in psoriasis. ( 29844603 )
2018
38
Psoriasis-like Dermatitis in Adulthood: a Skin Manifestation of Holocarboxylase Synthetase Deficiency. ( 29701239 )
2018
39
Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. ( 29707979 )
2018
40
Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting. ( 29952225 )
2018
41
Targeting IL-23 in psoriasis: current perspectives. ( 29441315 )
2018
42
Proposal of a new scoring formula for the DLQI in psoriasis. ( 29968311 )
2018
43
Serum VEGFR-3 as a potential biomarker in psoriasis. ( 29957828 )
2018
44
Subacute thyroiditis in a patient with psoriasis treated with a tumor necrosis factor-I+ inhibitor. ( 29460956 )
2018
45
Generalized pustular psoriasis: a review and update on treatment. ( 29573491 )
2018
46
Safety Proi-8le of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. ( 29972221 )
2018
47
An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice. ( 29961546 )
2018
48
Generalized Pustular Psoriasis ( 29630241 )
2018
49
Soluble Receptor for Advanced Glycation End Products: A Novel Biomarker for Psoriasis Severity with Therapeutic Implications? ( 29963680 )
2018
50
Effect of an Educational and Psychological Intervention on Knowledge and Quality of Life among Patients with Psoriasis. ( 29441294 )
2018

Variations for Psoriasis

Copy number variations for Psoriasis from CNVD:

7 (show all 27)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103 Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104 Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4 Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103 Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104 Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105 Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106 Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107 Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4 Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11 Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4 Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11 Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106 Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105 Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107 Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline-rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3, skin-derived Skin + 6.19 0.000
7 KRT6C keratin 6C, type II Skin + 5.98 0.000
8 SPRR2A small proline-rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A, type II Skin + 5.90 0.000
10 SPRR2B small proline-rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B, type II Skin + 5.39 0.000
12 SPRR2D small proline-rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein, beta 2, 26kDa Skin + 4.97 0.000
15 SPRR2C small proline-rich protein 2C (pseudogene) Skin + 4.90 0.000
16 C10orf99 chromosome 10 open reading frame 99 Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline-rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Skin + 4.33 0.000
21 SPRR1B small proline-rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16, type I Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline-rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 (psoriasis-associated) Skin + 3.89 0.000
29 IFI27 interferon, alpha-inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein-related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36, gamma Skin + 3.50 0.000
34 DEFB103B defensin, beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein, beta 6, 30kDa Skin + 3.38 0.000
37 SPRR2E small proline-rich protein 2E Skin + 3.24 0.000
38 POSTN periostin, osteoblast specific factor Skin - 3.14 0.000
39 CD36 CD36 molecule (thrombospondin receptor) Skin + 3.12 0.000
40 IGFL1 IGF-like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

Pathways related to Psoriasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR146A MIR200A MIR203A MIR21 MIR31

GO Terms for Psoriasis

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of blood vessel endothelial cell migration GO:0043536 9.26 MIR200A MIR31
2 negative regulation of endothelial cell proliferation GO:0001937 9.16 MIR146A MIR21
3 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 8.96 MIR146A MIR31
4 gene silencing by miRNA GO:0035195 8.92 MIR146A MIR200A MIR21 MIR31

Molecular functions related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR146A MIR200A MIR21 MIR31

Sources for Psoriasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....